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http://dx.doi.org/10.1016/j.stemcr.2017.08.010SUMMARYGeneration of hematopoietic stem cells (HSCs) from pluripotent stem cells (PSCs) could potentially provide unlimited HSCs for clinical
transplantation, a curative treatment for numerous blood diseases. However, to date, bona fide HSC generation has been largely unsuc-
cessful in vitro. We have previously described proof of concept for in vivo HSC generation from PSCs via teratoma formation. However,
our first-generation system was complex and the output low. Here, we further optimize this technology and demonstrate the following:
(1) simplified HSC generation using transcription factor overexpression; (2) improved HSC output using c-Kit-deficient host mice, and
(3) that teratomas can be transplanted and cryopreserved. We demonstrate that overexpression of Gfi1b, c-Fos, and Gata2, previously
reported to transdifferentiate fibroblasts into hematopoietic progenitors in vitro, can induce long-termHSC formation in vivo. Our in vivo
system provides a useful platform to investigate new strategies and re-evaluate existing strategies to generate HSCs and study HSC
development.INTRODUCTION
Pluripotent stem cells (PSCs) can differentiate into any
bodily cell type. Somatic cells can also be reprogrammed
to pluripotency by overexpression of ‘‘Yamanaka factors,’’
generating inducible PSCs (iPSCs) (Takahashi and Yama-
naka, 2006). Optimization of these technologies over the
past 10 years has enabled the safe generation of patient-
specific iPSCs for prospective clinical applications. Now
the major hurdle in the translational application of iPSC
technologies is developing strategies to differentiate PSCs
into clinically relevant functional cell types.
Adult hematopoietic stem cells (HSCs) reside in the bone
marrow (BM) and have the unique ability to reform the
entire blood system (Eaves, 2015). HSC function is defined
by a cell-intrinsic transcriptional program as well as cell-
extrinsic signaling emanating from the BM microenviron-
ment. Long-term HSC function provides the basis of BM
transplantation, a curative therapy for a range of hemato-
logical disorders. Derivation of functional HSCs from
PSCs has therefore been a long-sought goal of regenerative
medicine (Wahlster and Daley, 2016). However, we are
currently unable to generate truly functional HSCs from
PSCs in vitro. This is likely due to our inability to fully reca-
pitulate the complex and temporally dynamic in vivo
microenvironmental signaling program that specifies
HSCs during development (Medvinsky et al., 2011). In
mice, transplantable HSCs emerge from hemogenic endo-1024 Stem Cell Reports j Vol. 9 j 1024–1033 j October 10, 2017 j ª 2017 Th
This is an open access article under the CC BY-NC-ND license (http://creativthelial (HE) precursors, notably in the dorsal aorta (Zovein
et al., 2008). Expression of the transcription factor (TF)
Runx1 can be used to track this process (North et al.,
1999); live-cell imaging has captured hematopoietic
stem/progenitor cell (HSPC) formation at sites of Runx1+
HE cells (Bertrand et al., 2010; Boisset et al., 2010).
Certain attempts to generate HSCs thus far have used
transgene overexpression to either direct the differentia-
tion of PSCs, or alternatively, to transdifferentiate other so-
matic cell types. Several approaches have been reported to
generate hematopoietic cells in vitro (Doulatov et al., 2013;
Riddell et al., 2014; Sandler et al., 2014). In two very recent
reports, conversion of mouse and human endothelial cells
to engraftable HSCs was achieved by overexpression of
several TFs (Sugimura et al., 2017; Lis et al., 2017).
In another study, Pereira et al. (2013) reported that over-
expression of three TFs (Gfi1b, c-Fos, and Gata2) could
transdifferentiatemouse fibroblasts intoHE-like intermedi-
ates that could further mature into hematopoietic progen-
itor cells (HPCs). However, fully functional HSCs were not
generated by this method.
As an alternative, we (and others) have previously
demonstrated proof of concept for the in vivo generation
of fully functional HSCs from PSCs via teratoma formation
(Suzuki et al., 2013; Amabile et al., 2013). However, our
first-generation in vivo differentiation system (Suzuki
et al., 2013) had several limitations: (1) PSCs needed to be
co-injected with OP9 stromal cells and hematopoietice Author(s).
ecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Screening Transcription Factor Expression for Hematopoiesis within Teratomas
(A) Schematic diagram of the doxycycline (Dox)-inducible system for the expression of transcription factor (TF) combinations.
(B) Strategy to induce hematopoietic cells from lentivirally transduced iPSCs through teratoma formation. Dox was administrated for
4 weeks after teratoma size reached 2 cm in diameter, after which teratomas were collected for histological analysis.
(C) Representative H&E-stained teratoma sections, with morphological features labeled. Trabecular bone-like structure, TB (and black
arrows); bone marrow cells, BMCs (and red arrows); endothelial cells, ECs (and white arrows); epithelial, EPCs (and black arrows).
(legend continued on next page)
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cytokines (SCF and TPO) administered via micropump; (2)
we could not identify the site of HSC emergence; and; (3)
HSC formation was slow, taking 2–3 months. Here, we sys-
temically overcome these limitations and provide an opti-
mized in vivo HSC formation protocol. Furthermore, we
demonstrate that in vivo overexpression of Gfi1b, c-Fos,
and Gata2 during teratoma formation is sufficient to
generate functional long-term HSCs.RESULTS
Gfi1b, c-Fos, and Gata2 Overexpression Induces
Hematopoietic Cell Formation in Teratomas
Teratomas contain tissues from all three germ layers, and
we previously demonstrated that teratomas can generate
HSCs (Suzuki et al., 2013). However, this required co-injec-
tion of OP9 stromal cells and continuous administration of
cytokines (Suzuki et al., 2013). We hypothesized that in-
duction of TFs related to HSCs and/or the HSC microenvi-
ronment could improve HSC generation in teratomas. To
this end, we investigated three distinct TF combinations:
(1)Gfi1b, c-Fos, andGata2 (GFG), whichhave been reported
to generate HE-like cells and HPCs from fibroblasts (Pereira
et al., 2013); (2) Erg, HoxA9, and Rora (EAR), which have
been reported to generate HPCs during PSC embryoid
body formation (Doulatov et al., 2013), and (3) Foxc1, re-
ported to be highly expressed in CXCL12-abundant retic-
ular (CAR) cells, an important component of the HSC BM
niche (Omatsu et al., 2014).
To enable the identification of iPSC-derived HSCs, we
first established iPSCs from a C57BL/6-Ly5.1 mouse to
allow immunophenotypic discrimination from C57BL/6-
Ly5.2 host mouse blood cells. Next, we cloned the above
TFs into a doxycycline (Dox)-inducible (Tet-On) lentivirus
expression vector (Figure 1A). Stable iPSC lines were gener-
ated and Dox-inducible transgene expression was
confirmed using qPCR (Figure S1A). Next, we injected
C57BL/6-Ly5.1 iPSCs (2 3 106) subcutaneously into host
C57BL/6-Ly5.2 mice, and administered Dox for 4 weeks
once teratomas reached >2 cm in diameter (6–8 weeks
post-injection) to induce TF expression (Figure 1B). Impor-
tantly, this was undertakenwithout co-injection of stromal
cells or cytokines.
After the 4-week Dox exposure, we analyzed the periph-
eral blood (PB) of engraftedmice by flow cytometry and the
teratoma by histology (Figure 1B).We observed distinct dif-(D) Representative flow cytometric plots of CD45.1 and CD45.2 express
at 14–16 weeks after Ly5.1 iPSC injection.
(E) Average percentage of CD45.1+ PB cells in host mice. Data are the
(F) Average percentages of hematopoietic cell lineages within the CD
B220+, B cells; CD4+, CD4+ T cells; and CD8+, CD8+ T cells. Data are m
1026 Stem Cell Reports j Vol. 9 j 1024–1033 j October 10, 2017ferences between teratomas generated in the different
experimental regimens (Figures 1C and 1D). For example,
the GFG iPSC-derived teratomas contained a large number
of endothelial and epithelial-like cells byH&E staining (Fig-
ure 1C). By contrast, Foxc1-derived teratomas formed bone
cortices, cartilage, and BM-like cells (Figure 1C). While
CD45.1+ donor-derived blood cells were not detected in
the host PB following injected with wild-type iPSCs or
Foxc1 iPSCs, both EAR iPSCs and GFG iPSCs reconstituted
multi-lineage hematopoiesis 14–18 weeks post-injection
(Figures 1D and 1E), with GFG iPSCs generating approxi-
mately 2-fold more hematopoietic cells (Figures 1E and
1F). These data demonstrate that GFG iPSC-derived tera-
tomas differentiate into hematopoietic cells more effi-
ciently compared with the other groups.
To evaluate the potential consequences of the GFG
cassette on HSCs, we generated GFG transgenic mice
from GFG embryonic stem cells. Leaky expression could
not be detected (Figure S1B), and no difference in colony-
forming ability was seen (Figure S1C). Reactivation of the
reprogramming factors could also not be detected in
iPSC-derived CD45+ cells (Figure S1D).Identification ofHemogenic EndotheliumwithinGFG
iPSC-Derived Teratomas
Given that GFG expression directly induces HE-like
cells from mouse fibroblast in vitro (Pereira et al., 2013),
we hypothesized that endothelial cells (ECs) within the
GFG iPSC-derived teratomas (Figure 2A) might in fact
resemble HE cells. By co-staining with Cytokeratin and
CD31, we could identify CD31+ endothelial-lined cystic
structures, which were also CD144/VE-cadherin+ (Figures
S2A and S2B). We further confirmed the presence of
Runx1-expressing ECs in GFG teratoma sections by im-
munostaining for Runx1 and CD31 (Figure 2B). More-
over, we could even identify hematopoietic cell clusters
budding from these ECs (Figure 2B). CD45+ hematopoiet-
ic cells could also be identified within the endothelial
structures, suggesting teratoma vasculature was perfused
with blood (Figure S2C).
Runx1 enhancer activity can be used to identify HE cells
(Swiers et al., 2013). To study this in the teratoma, we estab-
lished iPSCs from a eR1-EGFP transgenic reporter mouse
(Ng et al., 2010). The activity of an enhancer for Runx1
(eR1), formerly called Runx1+24 or +23, is known to specif-
ically mark HE cells within CD31+ endothelium in theion in peripheral blood (PB) from teratoma-bearing Ly5.2 host mice
means ± SD from two independent experiments (n = 6). *p < 0.05.
45.1+ population in (E). Gr-1+, granulocytes; Mac-1+, macrophages;
eans ± SD from two independent experiments (n = 3).
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Figure 2. Identification of Hematopoietic-Generating Tissue in Teratomas
(A) Representative images from GFG teratoma sections stained with H&E. These tissues contain a large number of endothelial-like cells
(ECs), annotated with black arrows. Hematopoietic cells (HCs) appearing to directly bud from ECs are annotated with white arrows.
(B) Representative images from GFG iPSC-derived teratoma sections stained with Runx1 and CD31. Runx1+ cells were detected by DAB
(brown color) and CD31+ were detected by Bajoran purple (Purple color), with sites of double staining identified as putative sites of
hematopoietic cell emergence, as marked by white arrows.
(legend continued on next page)
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embryo as well as committed CD45+ HSPCs (Nottingham
et al., 2007). To comprehensively visualize all GFP+ cells
within the teratoma, we applied tissue clearing and 3D
volumetric imaging or CUBIC (Susaki et al., 2014) (Fig-
ure 2C). Using thismethod, wewere further able to identify
GFP+ endothelial structures within GFG-derived teratomas
(Figures 2D and 2E). Notably, GFP+ cells were much more
frequent within the GFG-derived teratomas than the con-
trols (Figure 2E).
We further confirmed that eR1-EGFP-iPSCs were giving
rise to GFP+CD45+ HSPCs by flow cytometric analysis of
the teratomas. We detected a distinct GFP+CD45+ cell pop-
ulation, which was nearly 10-fold higher in GFG-derived
teratomas compared with the controls (average value: con-
trol, 0.06% ± 0.02%; GFG, 0.8% ± 0.3%) (Figures 2F and
2G). Therefore, GFG expression induces eR1-EGFP expres-
sion within teratomas and generates GFP+CD45+ hemato-
poietic cells, similar to that described in vitro (Pereira
et al., 2013). However, the low frequency of teratoma-
derived blood cells in this system precluded our further
analysis of HSC formation and function. It is worth noting
that GFG induction in iPSCs could not induce eR1-GFP
expression, or surface markers associated with HE or he-
matopoietic cell commitment (Figure S2D), suggesting he-
matopoietic cell induction following GFG expression
occurred within the context of teratoma development/
differentiation.
Conditional c-Kit Deficiency Promotes Expansion of
iPSC-Derived HSPCs In Vivo
Adult HSCs take up lifelong residence in the BM. To
improve teratoma-derived hematopoietic cell frequencies,
we hypothesized that HSC-deficient hosts would pro-
mote expansion of iPSC-derived HSCs. HSCs can engraft
in c-Kit-deficient mice without irradiation (Cosgun et al.,
2014). We therefore generated host mice with inducible,
hematopoietic-specific c-Kit deletion by breeding C57BL/
6-Ly5.2 c-Kitflox/flox Mx1-Cre transgenic mice where c-Kit
deletion was achieved by poly(I:C) administration (Fig-
ure S3A). Importantly, white blood cell, hemoglobin, and
platelet counts were lower in c-Kit-deficient mice (c-KitD/D)
than in the controls (Figure S3B), and the BM was hypo-
cellular (Figure S3C). We further confirmed long-term
multi-lineage donor reconstitution in Ly5.2 c-KitD/D hosts
without irradiation following transplantation of 1 3 107
Ly5.1 BM donor cells (Figures S3D and S3E).(C) Representative images of teratoma tissue clearing in chemical coc
cleared on the right.
(D) Localization of eR1+ cells (green) and DAPI (blue) in 2D reconstr
(E) Localization of eR1+ cells (green) and DAPI (blue) in 3D reconstru
(F) Representative flow cytometric plots for CD45 and GFP expression
(G) Percentage GFP+CD45+ cells in teratomas, using gating displayed
1028 Stem Cell Reports j Vol. 9 j 1024–1033 j October 10, 2017Having validated a mouse model that was permissive to
HSC engraftment, we next wanted to determine whether
the c-KitD/D model could improve teratoma-derived HSC
formation. We injected GFG iPSCs subcutaneously into
Mx1-Cre;c-Kitflox/flox host mice and administered poly(I:C)
following teratoma formation (and Dox treatment) to
deplete host HPSCs (Figure 3A). After 4–6 weeks, we
observed a 10-fold increase in the frequency of iPSC-
derived hematopoietic cells within the PB of the c-KitD/D
hosts compared with control mice (control group,
0.02% ± 0.02%; c-Kit D/D, 0.3% ± 0.2%) (Figure 3B). We
also found similar increases in iPSC-derived cell frequencies
within the BM (control group, 0.01% ± 0.001%; c-KitD/D,
0.2% ± 0.1%) (Figure 3C). Notably, poly(I:C) did not
influence the generation of teratoma-derived PB cells in
wild-type mice (Figure S4A).
To assess whether these hematopoietic cells contain en-
graftable HSCs, we transplanted 1 3 107 whole bone
marrow cells (WBMCs) from teratoma-host mice into irra-
diated C57BL/6-Ly5.2 recipient mice (Figure 3A). We de-
tected CD45.1+ PB cells in multiple lineages over 16 weeks
(Figure 3D). To functionally confirm long-term HSC ca-
pacity within the original CD45.1+ cells, 1 3 107 WBMCs
from the primary recipients were transplanted into irradi-
ated secondary recipient mice. Multi-lineage CD45.1+ PB
cells could be detected long-term in these secondary recip-
ients (and even in tertiary recipients), demonstrating
long-term HSC activity (Figures 3D, S4B, and S4C). In
addition, we detected immunophenotypic CD45.1+C-
KIT+SCA-1+Lineage HPSCs in the BM of secondary recip-
ients (Figure 3G). However, we noted that a 30% reduction
in colony-forming units within the CD45.1+ WBMC
population compared with CD45.2+ host BM cells, sug-
gesting teratoma-derived BM cells are not identical to nor-
mally produced BM cells (Figures 3E, 3F, S4D, and S4E).
However, these data demonstrate that GFG expression
within teratomas generates functional HSCs that expand
within c-Kit-deficient mice.
Transplantable Teratomas Provided Stable and
Continuous Source of HSPCs
Finally, to improve on the time-consuming nature of these
experiments, we investigated the following: (1) serial trans-
plantation of freshly isolated teratomas and (2) use of cryo-
preservation of teratoma blocks. We performed transplan-
tation of freshly isolated or cryopreserved teratoma blocksktails and computational analysis (CUBIC); non-cleared on the left,
ucted image between eR1-derived and eR1-GFG-derived teratoma.
cted images between eR1-derived and eR1-GFG-derived teratoma.
in the teratoma from eR1-EGFP iPSC-derived teratomas.
in (F) (n = 3). *p < 0.05.
AB C
D
G
FE
(legend on next page)
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into host recipient mice (Figure 4A). In both cases, the
transplanted teratomas survived and expanded (Figure 4B).
Moreover, transplantable teratoma blocks generated he-
matopoietic cells that seeded the BM of c-KitD/D host mice
(Figure 4C). Using this transplantation approach, we are
able to shorten hematopoietic cell generation time by
5 weeks, from 10 to 5 weeks (Figure 4D). The frequency
of teratomas that generated CD45.1+ blood cells was also
higher in the transplanted hosts, compared with injec-
tion of iPSCs (Figure 4E). We also confirmed CD45.1+
WBMCs from these hosts could transplant into recipients
(Figure S4F). Combined, these data demonstrate that
transplantable teratomas constitute stable and continuous
sources of hematopoietic cells.DISCUSSION
Here, we report an optimized system to generateHSC in vivo
via teratoma formation for faster, higher-efficiency HSC
production from iPSCs without co-injection of stromal
cells or continuous provision of cytokines. While Pereira
et al. (2013) were able to generate HPCs from fibroblasts
in vitro by overexpressing GFG, transplantable HSCs could
not be detected. Here, we have demonstrated that within
an in vivo environment (iPSC-derived teratomas), GFG
expression generated functional long-term HSCs. Our
data therefore highlight the importance of in vivo evalua-
tion of directed and transdifferentiation approaches. We
envision in vivo HSC generation via teratoma formation
as an important assay to assess new (and existing) ap-
proaches to generate engraftable HSCs. We also highlight
the potential of our system to study mechanisms of HSC
generation using an eR1-EGFP reporter system (Ng et al.,
2010). In summary, we demonstrate that GFG overexpres-
sion in vivo within mouse teratomas can generate fully
functional HSCs.Figure 3. c-Kit Deficiency Promotes Expansion of Hematopoietic
(A) Strategy to induce HSCs from iPSCs using c-Kit deficient host m
4 weeks to induce GFG expression (as in Figure 1B). Host mice were th
teratoma-bearing mice were transplanted into irradiated mice, and PB
at 16 weeks after the primary transplantation.
(B) Representative flow cytometric plots for CD45.1 and CD45.2 expre
mice after 4–6 weeks poly(I:C) administration.
(C) Percentage CD45.1+ chimerism in the PB (left) and BM (right). Da
**p < 0.005, *p < 0.05.
(D) Percentage of (GFG iPSC-derived) CD45.1+ PB chimerism of in prim
(E and F) Colony potential of 2.0 3 104 host CD45.2+ and GFG-derive
Methocult. Total number of colonies displayed in (E) and colony typ
periments (n = 3). Colony cells were morphologically identified as neut
(M). **p < 0.005.
(G) Representative flow cytometric plots and gating for the Kit+Sc
transplanted with GFG teratoma-derived blood cells 24 weeks post-tra
1030 Stem Cell Reports j Vol. 9 j 1024–1033 j October 10, 2017EXPERIMENTAL PROCEDURES
Mice
C57BL/6-Ly5.2 (Ly5.2) and C57BL/6-Ly5.1 (Ly5.1) mice were
purchased from Japan SLC (Shizuoka, Japan) and Sankyo Lab
Service (Tsukuba, Japan), respectively. For generation of Mx1-Cre
c-Kitflox/flox mice, c-Kitlox66-71/lox66-71 mice (Kimura et al., 2011)
were crossed with Mx1-Cre mice transgenic mice (Kuhn et al.,
1995). Mice received 250 mg of poly(I:C) intraperitoneally seven
times every other day to induce Cre expression. Animal experi-
ments were approved by the Animal Care and Use Committee,
Institute of Medical Science, University of Tokyo.Cell Culture
Mouse iPSCs were obtained by reprogramming tail-tip fibroblasts
of C57BL/6-Ly5.1 mice with Oct4, Sox2, and Klf4, and then main-
tained as previously described (Nakagawa et al., 2008).Lentivirus
Inducible lentivirus vectors were derived from the self-inacti-
vating lentiviral vector CS-TRE-PRE-Ubc-tTA-I2G (Yamaguchi
et al., 2012). Lentiviral production was performed as previously
described (Shibuya et al., 2003).Reverse Transcription PCR
Total RNAwas extracted using TRIzol (Invitrogen) and reverse tran-
scribed (High Capacity cDNA RT Kit; Applied Biosystems). qPCR
was performed using the Universal Probe Library System (Roche
Diagnostics; see Table S1). Samples were normalized to Gadph
expression, using TaqMan probes (Applied Biosystems).Teratoma Formation
Twomillion murine iPSCs were administered subcutaneously into
C57BL/6(Ly5.2) or Mx1-Cre c-Kitflox/flox mice (6–10 weeks old)
with Matrigel. We measured teratoma growth every month
and analyzed the ratio of CD45.1+ cells in PB every month. Where
indicated, TF expression was induced after teratoma formation by
Dox (2 mg/mL) administration via the water supply for 4 weeks.Stem Cells from GFG-Derived iPSCs
ice. iPSCs were injected subcutaneously and Dox administered for
en administered polyI:C at weeks 14–16. At 20 weeks, WBMCs from
/BM chimerism tracked. Secondary transplantations were performed
ssion in the PB from teratoma-bearing C57BL/6 and c-Kit-deficient
ta are the means ± SD from two independent experiments (n = 6).
ary and secondary recipient mice (n = 5).
d CD45.1+ BM cells of secondary recipients, after 11-day culture in
e displayed in (F). Data are means ± SD from two independent ex-
rophils (n), macrophages (m), erythroblasts (E) and megakaryocytes
a1+Lineage fraction within the BM of secondary recipient mice
nsplantation. Lin, lineage negative cells; KSL, LinKit+Sca1+ cells.
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Figure 4. Transplantation and Freeze Preservation of Teratoma Blocks
(A) Strategy transplant and freeze-preserved teratomas for hematopoietic cell formation. Teratomas (26–30 weeks old) were divided into
(1.5 3 1.5 3 1.5 cm) blocks and were transplanted into c-Kit-deficient mice with 4 weeks of Dox administration (with or without initial
freeze preservation), followed by poly(I:C) administration.
(B) Average diameter of the transplanted teratoma blocks after transplantation (n = 3).
(legend continued on next page)
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After 4 weeks of Dox administration, mice received poly(I:C)
intraperitoneally.
BM Transplantation Assay
BM cells (1 3 107) from teratoma-bearing mice were transplanted
into lethally irradiated (9.5 Gy) wild-type C57BL/6-Ly5.2 recipient
mice. BM cells (1 3 107) from the primary recipient mice were
transplanted 16 weeks after primary BM transplantation into
lethally irradiated secondary recipients.
Flow Cytometry
PB and BM were stained with anti-mouse antibodies as detailed in
Table S2. Analysis was performed on a FACSCanto using Summit
software (Beckman Coulter), and the results were analyzed with
FlowJo.
Colony Assays
BM cells (20,000) were added to 1.1 mL of MethoCult GF M3434
(STEMCELLTechnologies) and cultured at 37Cwith 5%CO2. Col-
onies were counted after 11 days, cytospun onto slide glasses, and
subjected to Hemacolor staining (Merck) for morphological
examination.
Histopathology/Immunohistochemistry
Histological findings were assessed by H&E-stained sections of
paraffin-embedded teratoma tissue. For immunohistochemical
analysis of teratomas, sections were stained with anti-Runx1
monoclonal Ab (Abcam92336) followed by anti-rabbit IgG-HRP.
Antibody stainingwas detected byDAB staining followed by coun-
terstaining with hematoxylin. After heating the microscope slides
to 95C for 5 min, sections were stained with anti-CD31 mono-
clonal Ab (SPRING BIOSCIENCE SP38) followed by anti-rabbit
IgG-HRP. Antibody staining was detected by Bajoran Purple Chro-
mogen Kit (Biocare Medical).
3D Teratoma Imaging
Teratoma clearing protocols were slightly modified from the orig-
inal CUBIC protocol (Susaki et al., 2014). Teratomas were
collected and fixed in 4% paraformaldehyde solution for
2 days. For nuclear staining, teratomas were immersed in DAPI/
PBS solution at 37C for 3 days with gentle shaking. Tissues
were embedded in 4 mm diameter glass capillaries with 2%
agarose for imaging. Images were acquired using a Zeiss Z1 Light-
sheet microscope (Zeiss) and reconstituted into 3D images using
Zen software (Zeiss).
Statistics
Calculations of statistically significant differences between sam-
ples using the Student’s two-tailed t test were performed using
Prism 4 software. Error bars displayed are the SD.(C) Representative flow cytometric plots for CD45.1 and CD45.2 from th
blocks (n = 5).
(D) Average percentage CD45.1+ PB cells in host mice following transp
means ± SD from two independent experiments (n = 6 iPSCs, n = 16 t
(E) Frequency of teratomas giving rise to CD45.1 PB cells from transp
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